DealI am one happy camper that this deal did not go through. It was bad from the get go. What has not been reported is what the cost was to walk away and WHY was it terminated. Filament is bleeding cash at an alarming rate and only being replenished by issuing more and more stock. This company needs an impartial review of cash flow,s now and into the future. Along with it a review of all it,s operating costs including executive compensation. There is alway,s lot,s and smoke and mirrors about various studies being conducted in differant universities etc none of which put cash in the bank. As a significant shareholder i have become very worried about how long this corporate direction can go on.